Your browser doesn't support javascript.
loading
Shortening the Alzheimer's disease assessment scale cognitive subscale.
Levine, Stephen Z; Goldberg, Yair; Rotstein, Anat; Samara, Myrto; Yoshida, Kazufumi; Cipriani, Andrea; Iwatsubo, Takeshi; Leucht, Stefan; Furukawa, Toshiaki A.
Afiliación
  • Levine SZ; School of Public Health, University of Haifa, Haifa, Israel.
  • Goldberg Y; The Faculty of Data and Decision Science, Technion Israel Institute of Technology, Haifa, Israel.
  • Rotstein A; Department of Gerontology, University of Haifa, Haifa, Israel.
  • Samara M; Department of Psychiatry, Faculty of Medicine, University of Thessaly, Larissa, Greece.
  • Yoshida K; Department of Health Promotion and Human Behavior, Graduate School of Medicine/School of Public Health, Kyoto University, Kyoto, Japan.
  • Cipriani A; Department of Psychiatry, University of Oxford, Oxford, UK.
  • Iwatsubo T; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.
  • Leucht S; Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre, Oxford, UK.
  • Furukawa TA; Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Eur Psychiatry ; 67(1): e19, 2024 Feb 23.
Article en En | MEDLINE | ID: mdl-38389390
ABSTRACT

BACKGROUND:

A short yet reliable cognitive measure is needed that separates treatment and placebo for treatment trials for Alzheimer's disease. Hence, we aimed to shorten the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) and test its use as an efficacy measure.

METHODS:

Secondary data analysis of participant-level data from five pivotal clinical trials of donepezil compared with placebo for Alzheimer's disease (N = 2,198). Across all five trials, cognition was appraised using the original 11-item ADAS-Cog. Statistical analysis consisted of sample characterization, item response theory (IRT) to identify an ADAS-Cog short version, and mixed models for repeated-measures analysis to examine the effect sizes of ADAS-Cog change on the original and short versions in the placebo versus donepezil groups.

RESULTS:

Based on IRT, a short ADAS-Cog was developed with seven items and two response options. The original and short ADAS-Cog correlated at baseline and at weeks 12 and 24 at 0.7. Effect sizes based on mixed modeling showed that the short and original ADAS-Cog separated placebo and donepezil comparably (ADAS-Cog original ES = 0.33, 95% CI = 0.29, 0.40, ADAS-Cog short ES = 0.25, 95% CI =0.23, 0.34).

CONCLUSIONS:

IRT identified a short ADAS-cog version that separated donepezil and placebo, suggesting its clinical potential for assessment and treatment monitoring.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastornos del Conocimiento / Enfermedad de Alzheimer Límite: Humans Idioma: En Revista: Eur Psychiatry Asunto de la revista: PSIQUIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastornos del Conocimiento / Enfermedad de Alzheimer Límite: Humans Idioma: En Revista: Eur Psychiatry Asunto de la revista: PSIQUIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Reino Unido